 E16 |
|
Other disorders of pancreatic internal secretion |
| |
 E16.0 |
 |
Drug-induced hypoglycemia without coma |
| |
| Excludes1 |
diabetes with hypoglycemia without coma (E09.649)
|
| UseAdditionalCode |
code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)
|
|
|
| |
| E16.1 |
|
Other hypoglycemia |
| |
| Functional hyperinsulinism | | Functional nonhyperinsulinemic hypoglycemia | | Hyperinsulinism NOS | | Hyperplasia of pancreatic islet beta cells NOS |
| Excludes1 |
diabetes with hypoglycemia (E08.649, E10.649, E11.649, E13.649)
hypoglycemia in infant of diabetic mother (P70.1)
neonatal hypoglycemia (P70.4)
|
|
|
| |
| E16.2 |
|
Hypoglycemia, unspecified |
| |
|
|
| |
| E16.3 |
|
Increased secretion of glucagon |
| |
| Hyperplasia of pancreatic endocrine cells with glucagon excess |
|
|
| |
| E16.4 |
|
Increased secretion of gastrin |
| |
| Hypergastrinemia | | Hyperplasia of pancreatic endocrine cells with gastrin excess | | Zollinger-Ellison syndrome |
|
|
| |
| E16.8 |
|
Other specified disorders of pancreatic internal secretion |
| |
| Increased secretion from endocrine pancreas of growth hormone-releasing hormone | | Increased secretion from endocrine pancreas of pancreatic polypeptide | | Increased secretion from endocrine pancreas of somatostatin | | Increased secretion from endocrine pancreas of vasoactive-intestinal polypeptide |
|
|
| |
| E16.9 |
|
Disorder of pancreatic internal secretion, unspecified |
| |
| Islet-cell hyperplasia NOS | | Pancreatic endocrine cell hyperplasia NOS |
|
|